NCT06081803Active, not recruitingPhase 3
Evolocumab in STEMI
The Effect of Evolocumab on Infarct Size in Patients With ST-segment Elevation Myocardial Infarction; Prospective, Randomized, Open Label, Controlled Trial
Source: ClinicalTrials.gov · Last updated 19 Jun 2025
Brief summary (registry, in English)
The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary percutaneous coronary intervention(PCI). All study participants will undergo a cardiac MRI 4 weeks after primary reperfusion. The evolocumab group will receive 420 mg before PCI via subcutaneous injection.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 166 (estimated)
- First submitted
- 30 Sept 2023
- Start date
- 5 Dec 2020
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Sejong General Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT06081803
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 166
- From 5 Dec 2020 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of myocardial infarction
- Previous history of coronary bypass surgery
Other illness
- Cardiogenic shock that lasts more than 10 minutes or cardiac arrest
Lab values
- Serum creatinine level is \>2.5mg/dL or dialysis is required
Other
- Occlusion of the left main coronary artery
- Pregnant or have a plan of pregnancy
Who the study is looking for
- Typical ischemic chest pain persists for more than 30 minutes
- An elevation of an ST segment greater than 1 mm in two consecutive leads or new-onset left bundle branch block
- Presenting more than 12 hours after the onset of symptoms
Age in the registry: 30 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SeJong General Hospital Coordinator of this site? Confirm its status | Bucheon-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.